Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -16.57% is 164% below its 5-year average of 25.95%, around the middle of its 5-year range (-65.81%–76.91%).
155.77% below its 12-month average of 29.71%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 76.91%.
GROSS MARGIN
-16.57%
GROSS MARGIN AVG TTM
29.71%
GROSS MARGIN AVG 3Y
34.79%
GROSS MARGIN AVG 5Y
25.95%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-155.77%
CURRENT VS 3Y AVG
-147.63%
CURRENT VS 5Y AVG
-163.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-138.62%
vs the sector median at left
Anteris Technologies Global Corp.
Market Cap
$734.10M
Gross Margin
-16.57%
TTM Avg
29.71%
3Y Avg
34.79%
5Y Avg
25.95%
Market Cap
$719.64M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$749.55M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$709.33M
Gross Margin
60.02%
TTM Avg
59.55%
3Y Avg
55.45%
5Y Avg
55.70%
Market Cap
$707.86M
Gross Margin
100.27%
TTM Avg
50.13%
3Y Avg
25.07%
5Y Avg
10.71%
Market Cap
$767.46M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
Market Cap
$698.60M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$774.32M
Gross Margin
40.44%
TTM Avg
20.22%
3Y Avg
20.22%
5Y Avg
20.22%
Market Cap
$775.72M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | -16.57% | 29.71% | 34.79% | 25.95% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | 0.00% | 0.00% | 0.00% | 0.00% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | 0.00% | 0.00% | 25.00% | 50.00% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 60.02% | 59.55% | 55.45% | 55.70% |
| Helus Pharma Inc. (HELP)vs › | $707.86M | 100.27% | 50.13% | 25.07% | 10.71% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | 100.00% | 141.50% | 99.31% | 94.19% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | 40.44% | 20.22% | 20.22% | 20.22% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Geron Corporation (GERN)vs › | $776.24M | 97.42% | 97.90% | 98.95% | -3197.94% |
Gross Margin
-16.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 76.91% |
| 2026-03-31 | -9.92% |
| 2025-12-31 | -65.81% |
| 2025-09-30 | 71.33% |
| 2025-06-30 | 76.05% |
| 2025-03-31 | 62.77% |
| 2024-12-31 | 61.25% |
| 2024-09-30 | 42.32% |
| 2024-06-30 | 50.58% |
| 2024-03-31 | 38.25% |
| 2023-12-31 | 34.33% |
| 2023-09-30 | 7.20% |
| 2023-06-30 | 6.97% |
| 2023-03-31 | 66.71% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
